Allergen-induced airway inflammation and its therapeutic intervention by O'Byrne, Paul M
3 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org
Allergen inhalation challenge has been useful for examining the mechanisms of allergen-induced airway inflammation and the associated 
physiological changes and for documenting the efficacy of drugs to treat asthma. Allergen inhalation by a sensitized subject results in acute 
bronchoconstriction, beginning within 15-30 min and lasting 1-3 hr, which can be followed by the development of a late asthmatic response. 
Individuals who develop both an early and late response after allergen have more marked increases in airway hyperresponsiveness, and greater 
increases in allergen-induced airway inflammation, particularly in airway eosinophils and basophils. All of the currently available and effective 
treatments for asthma modify some aspects of allergen-induced responses. These medications include short-acting and long-acting inhaled b2-
agonists, inhaled corticosteroids, cromones, methylxanthines, leukotriene inhibitors, and anti-IgE monoclonal antibody. In addition, allergen 
inhalation challenge has become a useful method which can, in a very limited number of patients, provide key information on the therapeutic 
potential of new drugs being developed to treat asthma.
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INTRODUCTION
Asthma is a chronic inflammatory disease of the airways, 
which is characterized by the characteristic symptoms of dys-
pnea, chest tightness, cough and wheezing, and by variable air-
flow obstruction and airway hyperresponsiveness to a wide va-
riety of physical and inhaled chemical stimuli. Over the past 40 
yr, very effective medications have been developed to treat 
asthma, the most effective of which are inhaled b2-agonists for 
acute symptom relief and inhaled corticosteroids (ICS) for long 
term management.
1 Important insights into the optimal man-
agement of asthma were made in the early 1980’s, when the 
central role of airway inflammation was identified to be impor-
tant in asthma pathogenesis, even in very mild disease.
2 This 
resulted in a change of focus from the relief of symptoms with 
frequent use of inhaled short acting b2-agonists, to the preven-
tion of symptoms and asthma exacerbations by the regular use 
of ICS. This approach is extremely effective in the majority of 
asthmatic patients, and in those who remain symptomatic de-
spite ICS treatment, the combination of ICS and a long-acting 
inhaled b2-agonists (such as formoterol or salmeterol) is gener-
ally sufficient to control asthma.
3
Asthma treatment guidelines have identified that the primary 
goal of management is to achieve optimal asthma control.
1 
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Asthma control means the minimization of night time and day-
time symptoms, and no activity limitation, rescue bronchodila-
tor use or airway narrowing. The search for new and effective 
asthma treatments has persisted and the approaches devel-
oped to assess these new treatment approaches have changed 
in light of the appreciation of inflammation as central to asthma 
pathophysiology and the focus on asthma control as the most 
important treatment outcome. This review will focus on the 
value and limitations of allergen inhalation challenge and its 
associated increase in airway inflammation in the evaluation of 
new therapeutic options for asthma.
ACTIVITY vs EFFICACY vs EFFECTIVENESS
Drug development is a 4 phase process. Phase I is the evalua-
tion of the new pharmacological entity for safety in normal vol-
unteers; although this phase is sometimes also used to look for 
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some evidence of activity. Phase II is when the “proof of con-
cept” study are done, and in studies for new entities in asthma, 
this is usually in mildly symptomatic patients with airflow ob-
struction, or in a clinical model of allergic inflammation. These 
studies are really examining for activity of the new entity in 
asthmatic airways and evidence of this activity does not always 
translate to evidence of efficacy in asthma. Also, these Phase II 
studies are usually small in size and of short duration, which 
provides little information of the safety of the entity in asthmat-
ic patients. Phase II is sometimes divided into Phase IIa, where 
the proof of concept study is done, and Phase IIb, where the en-
tity is evaluated in small studies of more symptomatic patients, 
to help develop the designs for the efficacy studies. Efficacy is 
evaluated in Phase III studies, which are designed to meet the 
requirements of regulatory agencies to show both efficacy and 
safety in the patient population for whom the new drug is to be 
prescribed. These studies are large (often >1,000 patients) and 
long (usually 1 yr of treatment). Evidence of efficacy is required 
in two such studies to obtain regulatory approval of the new 
treatment. The requirement for the outcomes to be evaluated 
in these Phase III studies differs in different countries granting 
regulatory approval. The final phase of clinical trial develop-
ment involves Phase IV studies, conducted after drug approval 
has been obtained. These studies are usually used to best posi-
tion the drug in the marketplace and to collect additional infor-
mation on safety. However, very few new drugs for asthma have 
been formally evaluated for effectiveness, which is the useful-
ness of the drug in the real world setting. 
ALLERGEN INHALATION CHALLENGE
In 1873, Blackley published a monograph describing grass 
pollen as the cause of these seasonal symptoms of allergic rhi-
nitis and seasonal asthma.
4 The late asthmatic response (LAR), 
which occurs 3 to 8 or more hours after allergen exposure, is 
now recognized as clinically more important than the early 
asthmatic response (EAR). In the 1950’s, Herxheimer identified 
that many of patients undergoing allergen hyposensitization 
complained of late symptoms, and he record the development 
of allergen-induced LAR in a significant number of patients, 
more common with house dust than with pollen.
5 It is now rec-
ognized that inhaled allergens by a sensitized subject results in 
acute bronchoconstriction, usually beginning within 15-30 min 
and lasting 1-3 hr. This is called the EAR. This can then be fol-
lowed by the development of an LAR beginning after the spon-
taneous resolution of the EAR, but which is more insidious in 
onset, gradually worsening over 3-12 hr, is more prolonged and 
often more severe than the EAR (Fig. 1).
6 Individuals who de-
velop both an EAR and LAR after inhaled allergen (dual re-
sponders) also have more marked and prolonged increases in 
airway hyperresponsiveness,
7,8 and greater increases in aller-
gen-induced airway inflammation, particularly in airway eo-
sinophils
3,9 and basophils.
10 This clinical model of allergen in-
halation challenge has been extremely useful for examining the 
mechanisms of allergen-induced airway inflammation and the 
associated physiological changes and for documenting the effi-
cacy of drugs to treat asthma. 
It is now known that inhaled allergen induced their airway re-
sponses by cross-links antigen-specific immunoglobulin (Ig)E 
that is bound to IgE receptors (FCeRI) on mast cells resident in 
the airway and circulating basophils. This is followed by mast 
cell degranulation to release a variety of preformed mediators 
(e.g., histamine),
11 as well as the up regulation of eicosanoid 
pathways to produce newly formed mediators (e.g., leukotri-
enes, prostaglandins) of bronchoconstriction,
12 which also lead 
to increasing vascular permeability. Indeed, allergen-induced 
bronchoconstriction occurring during the EAR and LAR can be 
abolished by treatment with a combination of anti-histamine 
and leukotriene antagonists,
13 indicating that histamine and 
cysteinyl leukotrienes together are responsible for these aller-
gen-induced effects.
PHARMACOLOGICAL MODIFICATION OF ALLERGEN-
INDUCED RESPONSES
All of the currently available and effective treatments for asth-
ma modify some aspects of allergen-induced responses. These 
medications include short-acting and long-acting inhaled b2-
agonists (SABAs and LABAs), inhaled corticosteroids (ICS), 
cromones, methylxanthines, leukotriene inhibitors, and anti-
Fig. 1. The effect of therapy on the airway response to inhaled allergen; dem-
onstrating time course of the mean (SD) decline in FEV1 (expressed as percent 
of pre-challenge FEV1 values) following allergen challenge to assess the effi-
cacy of ten days of treatment with an inhaled corticosteroid (budesonide; 400 
mcg daily) and a leukotriene antagonist (montelukast; 10 mg daily) on the early 
and late airway response to inhaled allergen in ten asthmatic subjects. Signifi-
cant attenuation of the early response was observed with either montelukast 
or the combination of budesonide and montelukast when compared with pla-
cebo. Significant attenuation of the late airway response was observed by all 
three active treatment regimens when compared with placebo.
49
Time post-allergen (hr)
%
 
C
h
a
n
g
e
 
i
n
 
F
E
V
1
5
o
-5
-10
-15
-20
-25
-30
-35
0 1 2 3 4 5 6 7
Placebo
Budesonide
Montelukast
CombinationAllergy Asthma Immunol Res. 2009 October;1(1):3-9.  doi: 10.4168/aair.2009.1.1.3
Allergen-induced airway inflammation AAIR 
5 http://e-aair.org
IgE monoclonal antibody.
Inhaled b2-agonists
Treatment with SABAs immediately before allergen inhala-
tion inhibits or reverses the EAR and, if administered during 
the LAR, can partially reverse the LAR, when it is not too severe; 
however, they neither prevent the LAR, nor allergen-induced 
airway inflammation. By contrast, the regular use of SABAs has 
been demonstrated to enhance most aspects of the allergen-in-
duced airway responses including the EAR,
14 the LAR
15 and the 
allergen-induced airway inflammation.
16 This evidence provid-
ed part of the rationale for avoiding the regular use of SABAs as 
monotherapy for asthma. 
LABAs are difficult to evaluate because of their prolonged 
bronchodilator, as well as functional antagonist effects. Func-
tional antagonism means their ability to prevent the onset of 
bronchoconstriction. Initial reports showing inhibition of EAR 
and LAR and induced AHR were thought to represent more 
than just the functional antagonist effect.
17 However, subse-
quent studies have generally shown minimal inhibition of the 
allergen-induced inflammation,
18 and it is currently believed 
that LABAs act mainly as functional antagonists in their inhibi-
tion of allergen-induced airway responses.
19-25 
Methylxanthines
Theophylline has a prolonged effect as a weak bronchodilator 
and a functional antagonist, which results in at most partial in-
hibition of the LAR.
26-30 A small study demonstrated the partial 
inhibition of the LAR, but little effect on the induced AHR.
30 
There are few studies addressing allergen-indcued airway in-
flammation, however, one study showed no inhibition of aller-
gen-induced airway eosinophilia, but a small reduction in air-
way activated T cells.
31
Inhaled corticosteroids
The most important controller medications for asthma are 
ICS. They are known to improve all aspects of asthma control,
1 
reduce eosinophilic airway inflammation
32 and reduce some 
components of airway remodelling.
32 ICS also have profound 
effects on allergen-induced airway responses. When used in 
single dose shortly before allergen challenge (or in the interval 
phase between the EAR and the LAR),
33 ICS demonstrate no ef-
fect on the EAR, but markedly inhibit the LAR.
19,34-36 Regular 
treatment with ICS for several weeks improves the EAR, abol-
ishes the LAR and markedly reduces allergen-induced airway 
inflammation.
37-41
Cromones
The cromones consist of two drugs, cromoglycate and nedo-
cromil. The earliest studies of pharmacoprotection against al-
lergen-induced responses were done with cromoglycate. These 
studies demonstrated that when used before, but not after, al-
lergen challenge cromoglycate inhibits allergen-induced EAR, 
LAR, and allergen-induced airway hyperresponsiveness.
34,35,42-44 
These data were used to support the mechanism of action of 
the cromones as inhibiting allergen-induced mast cell degran-
ulation. There are no studies addressing the effects of treatment 
with either cromoglycate or nedocromil on allergen-induced 
airway inflammation.
Leukotriene inhibitors
Leukotriene inhibitors inhibit either the production of the 
cysteinyl leukotrienes (5-lipoxygenase inhibitors) or the action 
of cysteinly leukotrienes on their receptor (Cys LT1 receptor an-
tagonists). Treatment with leukotriene inhibitors attenuates all 
aspects of allergen-induced airway responses. They attenuate 
the EAR,
45-50 and do so to a greater extent than do ICS,
49 but are 
less effective than ICS in their ability to attenuate the LAR (Fig. 
1), or allergen-induced AHR.
49 Leukotriene inhibitors also 
markedly reduced allergen-induced airway eosinophilia to a 
similar extent as ICS (Fig. 2).
49,50 
Various histamine antagonists (H1 blockers) have been exam-
ined with the allergen challenge model and have been demon-
strated to have small degrees of protection against the EAR, 
with little effect on the LAR.
50-57 Of interest, however, the combi-
nation of a leukotriene antagonist and a H1 blocker completely 
abolishes both the EAR and LAR.
13 This means that the bron-
choconstriction that develops after allergen inhalation is 
caused by the release of histamine and the cysteinyl leukotri-
enes, likely from mast cell activation causing the EAR and baso-
phil activation causing the LAR.
10
Fig. 2. The mean (SD) percentage of sputum eosinophils before and after an 
inhaled corticosteroid (budesonide) and a leukotriene antagonist (montelukast) 
before and following an allergen inhalation challenge. There was a subsequent 
reduction in the allergen-induced eosinophilia in the presence of all treatments.
*Indicates significant difference from pre-allergen value in the same treat-
ment group. Filled triangles indicate a significant difference from placebo at 
the same time point.
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Anti-IgE monoclonal antibody
Allergen inhalation challenge was used in two of the pivotal 
early investigations in the study of anti-IgE (omalizumab) in 
asthma.
58,59 Following treatment with anti-IgE, despite adminis-
tration of approximately twice as much allergen compared to 
the placebo treatment, subjects had marked reduction in the 
LAR.
59
The evaluation of ineffective therapies for asthma
The consistent demonstration of the benefits of drugs effec-
tive for asthma treatment on aspects of allergen-induced air-
way responses has resulted in allergen inhalation challenge be-
coming the most common method for the evaluation of new 
therapies for asthma (particularly if these are thought to have 
anti-inflammatory properties). Several drugs candidates have 
failed to modify allergen-induced responses and have also 
failed in larger clinical trials in asthma. Perhaps the best exam-
ple of this was the evaluation of esterase-sensitive ICS. These 
were corticosteroids which were rapidly metabolized by ester-
ases in the blood and therefore had the profile of being active in 
the airway, but potentially having no corticosteroid side effects. 
An interesting study was performed with one such molecule, 
which had been demonstrated not to work in clinical trials in 
asthma. This clinically ineffective esterase-sensitive ICS was 
compared with the clinically effective ICS, budesonide, in a sin-
gle dose trial involving allergen inhalation challenge. This study 
demonstrated that allergen challenge was able to differentiate 
between the clinically effective and clinically ineffective corti-
costeroid with regard to its effect on the allergen-induced 
LAR.
36 There are other examples of candidate drugs failing to 
protect against allergen challenge and failing in clinical trials. 
These include platelet activating factor (PAF) antagonists,
60,61 
thromboxane inhibitors,
62,63 VLA4 antagonists,
64 and inhaled 
leukotriene inhibitors.
65
The results of these studies suggest that a well conducted and 
interpreted allergen challenge study can be of value to predict 
efficacy or lack of efficacy of asthma controller therapies. Thus, 
drugs which inhibit the asthmatic responses, particularly aller-
gen-induced LAR, allergen-induced increase in AHR and aller-
gen-induced inflammation are generally effective in asthma 
therapy (Table 1). Perhaps of more value in drug development 
for asthma is that compounds that have not influenced the al-
lergen-induced late sequelae have never been subsequently 
proven to be effective in asthma treatment (Table 1). Thus, the 
test has a moderate positive predictive value, but an excellent 
negative predictive value. 
INVESTIGATION OF NEW AGENTS TO STUDY THE 
PATHOPHYSIOLOGY OF ALLERGIC RESPONSES
A large number of new molecules targeting various mecha-
nisms or pathways of the airway inflammatory process are un-
der scrutiny and considerable efforts will be devoted to deter-
mine if these agents may be clinically useful and improve 
airway inflammatory conditions such as asthma and rhini-
tis.
66,67 Allergy is a key mechanism leading to both the develop-
ment and persistence of airway inflammation and structural 
changes that may result in symptomatic asthma and rhinitis.
68 
Methods that could rapidly determine if a new product will be 
useful in treating those conditions are welcome. 
With standardized methods and validated outcomes, the al-
lergen bronchoprovocation test has become such tool which 
may quickly, in a very limited number of patients, provide key 
information on the therapeutic potential of the tested agent.
36 
As stated earlier in this manuscript, the test may indicate that 
the drug will be ineffective to treat asthma, for example, al-
though it does not provide accurate data on the degree of thera-
peutic efficacy of the agent. Nevertheless, as an initial “screen-
ing test” , it may avoid spending large amount of money and 
resources to evaluate its clinical usefulness.
Not only can this method help forecast clinical efficacy of the 
agent, but it may provide valuable information on how the 
agent is influencing the pathophysiology of immune responses 
and airway inflammation. With the new non-invasive methods 
of assessment of airway inflammation such as induced-sputum 
analysis, exhaled NO or exhaled breath condensate analysis 
(e.g., isoprostanes, pH, etc.) various aspects of the inflammato-
ry response may be explored.
69,70
Although there are still limitations to these tests, standardiza-
tion procedures and improved methods of measurement of 
various mediators are being developed, as well as surrogate 
Table 1. Examples of drugs studied using allergen inhalation challenge
True 
positives*
True 
negatives
†
False 
positives
‡
False 
negatives
§
Conventional 
  ICS
Esterase-sensitive 
  steroids
Anti-CD11a NIL
LABA PAF antagonists PGE2
Combination 
  ICS/LABA
Inhaled anti-LTs PGE1 analogues
SABA Thromboxane antagonists Anti-histamines
Anti-LT Selectin inhibitors
Anti-IgE
Theophylline
*True positives are those drugs which modify the challenge and have been 
shown to be effective in asthma; 
†True negatives are drugs which did not 
modify allergen challenge and which have failed in larger clinical trials of 
asthma patients; 
‡False positives are drugs which modified the challenge, but 
which are not useful to treat asthma; 
§False negatives would be drugs which 
did not modify the challenge, but are useful to treat asthma. 
No false negatives have been identified to date.
ICS, inhaled corticosteroids; LABA, long acting b2-agonists; SABA, short act-
ing b2-agonists; Anti-LT, anti-leukotrienes; PAF, platelet activating factor; PGE, 
prostaglandin E.Allergy Asthma Immunol Res. 2009 October;1(1):3-9.  doi: 10.4168/aair.2009.1.1.3
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markers of airway remodelling processes. The allergen bron-
choprovocation test therefore provides a dynamic model to 
evaluate various clinical, physiological and inflammatory 
changes following the acute trigger of the inflammatory cas-
cade. The newly developed low dose allergen challenges may 
as well be useful, in mimicking more closely natural exposures. 
CONCLUSIONS
When embarking on the clinical development of therapeutic 
agents in airway disease, designing effective studies to investi-
gate the airway response requires an understanding of the 
available outcomes that are clinically relevant, such as asthma 
exacerbations and asthma control. These should also be con-
sidered in association with the appropriate standardized physi-
ological and biochemical markers to validate efficacy, such as 
markers for inflammation and airway hyperresponsiveness; the 
hallmarks of dysfunction in airway disease that are likely the 
targets of a new therapeutic agent. All outcome measures, 
whether chosen as primary or secondary outcomes, may have 
certain limitations that need to be understood before they are 
applied in an effort to maximize their usefulness in establishing 
efficacy of a therapeutic agent. 
The practical and safety considerations of a chosen outcome 
measure, in particular those that are more invasive, should be 
well understood and carefully considered. When designing a 
clinical trial, prior studies that demonstrate the success of 
known therapies in airway disease should also be considered in 
an effort to demonstrate equivalent or superior efficacy and 
safety compared to existing therapies. Finally, and with no less 
importance, the most appropriate patient population at each 
stage of development of a therapeutic agent needs to be select-
ed that reflects the broadest applicable patient population that 
will translate to benefits in the real world population with air-
way disease.
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